In a significant move for the interventional spine market, Tampa-based medical device manufacturer PainTEQ has officially announced the US commercial launch of TRAQ, a sophisticated new implant system designed for posterior sacroiliac (SI) joint fusion. This launch marks a pivotal expansion of the company’s clinical toolkit, positioning TRAQ alongside its flagship LINQ system to provide physicians with a broader array of solutions for patients suffering from chronic SI joint dysfunction.
The introduction of TRAQ underscores PainTEQ’s commitment to refining minimally invasive surgical (MIS) techniques. By utilizing the same established posterior approach that surgeons have become accustomed to with the LINQ system, PainTEQ aims to minimize the learning curve for interventionalists while offering a robust mechanical solution for joint stabilization.
The Mechanical Innovation: Bi-Cortical Fixation
At the heart of the TRAQ system lies a design philosophy centered on structural integrity and biological integration. Unlike traditional stabilization methods that may rely on singular anchoring points, TRAQ is engineered to provide bi-cortical fixation.
The implant features unique, triangular piercing barbs specifically designed to engage both the sacral and iliac cortices. By securing the implant across both sides of the joint, the system creates a high-stability environment conducive to fusion. To further enhance clinical outcomes, the device incorporates a pre-filled graft window placed precisely at the joint interface. This feature is intended to facilitate osteointegration, encouraging natural bone growth and long-term stabilization of the SI joint.
The procedure itself is highly refined for the outpatient setting. The implant is introduced through a small, one-inch incision, reflecting the industry-wide shift toward procedures that reduce patient trauma, decrease recovery times, and lower the risks associated with more invasive open-back surgeries.
Chronology: From Concept to Clinical Application
The path to the TRAQ launch has been marked by rigorous design iterations and strategic regulatory milestones.
- Foundation: Building upon the success of the LINQ system, which helped pioneer the posterior SI joint fusion space, PainTEQ’s R&D team spent years analyzing clinical feedback and biomechanical data to determine how to further enhance fusion stability.
- Design Phase: Engineers finalized the geometry of the triangular piercing barbs, ensuring the device could reliably engage the dense cortical bone of both the sacrum and the ilium.
- Regulatory Alignment: Throughout 2024, PainTEQ continued to strengthen its intellectual property portfolio. In December 2024, the company secured a critical new US patent for its SI joint stabilization technology, laying the legal and technical groundwork for the introduction of new hardware, including the TRAQ system.
- First Clinical Use: The milestone of the first clinical procedure was achieved by Dr. Timothy Deer, CEO of The Spine and Nerve Center of the Virginias and founder of the American Society of Pain and Neuroscience. This successful initial procedure signaled the readiness of the system for broader commercial distribution.
- Market Entry: The official commercial rollout commenced in mid-2026, with PainTEQ establishing distribution channels across the United States to ensure interventionalists have rapid access to the technology.
Supporting Data and the TRAQTION Study
PainTEQ is not merely relying on the mechanical prowess of the TRAQ implant; the company is investing heavily in empirical validation. To provide the medical community with high-quality, real-world evidence, the company has initiated the TRAQTION study.
This prospective, multi-centre, post-market clinical trial is designed to rigorously assess both the safety profile and the efficacy of the TRAQ system in a standard clinical environment. The study has already secured central institutional review board (IRB) approval from WCG IRB, a major step in ensuring that the research adheres to the highest ethical and methodological standards.
The study protocol aims to enroll up to 100 participants across ten distinct locations in the United States. Following the initial procedure, researchers will monitor patients for up to 24 months. By tracking pain scores, functional improvement, and fusion rates over this two-year period, PainTEQ aims to generate a comprehensive data set that can guide future treatment protocols and support long-term insurance reimbursement strategies.
Official Responses and Strategic Vision
The leadership team at PainTEQ views the launch of TRAQ as a natural evolution of the company’s mission. By diversifying its product line, the firm aims to capture a larger share of the interventional spine market while addressing the diverse anatomical needs of patients.
Shanth Thiyagalingam, CEO of PainTEQ, emphasized the strategic importance of the launch:
"The launch of TRAQ represents the next evolution of our posterior SI joint fusion platform. PainTEQ helped pioneer posterior SI joint fusion with LINQ, and TRAQ builds on that foundation with a new implant designed to further expand physician treatment options while we continue generating high-quality clinical evidence. Our goal is to provide surgeons with the most effective, least invasive tools available to alleviate the debilitating pain associated with SI joint dysfunction."
Dwayne Polzer, Vice President of Research and Development at PainTEQ, provided insight into the technical design:
"TRAQ’s triangular piercing barbs were an intentional design choice. They engage both the sacral and iliac cortices, which is what this joint needs to stabilize. When we developed this, we were looking at the biomechanical challenges of the SI joint. By ensuring we lock into both cortices, we move beyond simple fixation toward a more reliable, durable fusion process."
Implications for the Interventional Spine Market
The introduction of the TRAQ system has several far-reaching implications for the medical device industry and the field of pain management:
1. Shift Toward Specialized Fusion
The ability to perform bi-cortical fixation via a posterior, one-inch incision allows for a more standardized approach to SI joint fusion. As more interventionalists adopt these techniques, we may see a transition of SI joint fusion procedures from complex orthopedic surgeries to routine outpatient interventional procedures.
2. Competitive Landscape
PainTEQ’s dual-offering of LINQ and TRAQ creates a formidable portfolio. Surgeons now have a choice of implant geometry based on the specific anatomical requirements of the patient, allowing for a "personalized" approach to fusion that was previously less accessible.
3. The Demand for Real-World Evidence (RWE)
By proactively launching the TRAQTION study, PainTEQ is acknowledging the growing demand from payers and healthcare systems for long-term clinical data. In the current healthcare climate, a device’s success is measured not just by its ease of use, but by its ability to demonstrate sustained, long-term pain relief and improved patient quality of life.
4. Patient Outcomes
For the millions of Americans suffering from chronic SI joint pain—a condition often misdiagnosed as lumbar radiculopathy or general lower back pain—the availability of new, refined technologies like TRAQ offers hope for a return to normalcy. By providing a stable, fusion-conducive environment, PainTEQ is aiming to minimize the risk of implant migration and secondary surgical interventions.
Conclusion
The launch of the TRAQ system by PainTEQ marks a significant milestone in the treatment of sacroiliac joint dysfunction. By combining a minimally invasive posterior approach with the mechanical reliability of bi-cortical, triangular-barb fixation, the company is positioning itself at the forefront of spinal interventional technology.
As the TRAQTION study progresses over the next two years, the industry will be watching closely to see how this new implant performs in the hands of a broader range of practitioners. With a clear focus on clinical evidence, intellectual property development, and physician training, PainTEQ appears well-equipped to maintain its momentum in the competitive spinal device landscape, ultimately providing more options for patients who have long been underserved by traditional treatment pathways.
About the Author
